Galderma R&D clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   Nemolizumab · Moderate-to-severe Atopic Dermatitis

   Recruitment opened

   Also in this update: Primary completion pushed from Sep 28, 2027 to Oct 28, 2027

   Galderma R&D·Phase 3· NCT07762833· Registry history of NCT07762833 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.